Melbourne-based biotechnology startup Diag-Nose.io has today announced the completion of a highly oversubscribed $3.15 million seed funding round, led by Breakthrough Victoria with participation from Radar Ventures and SPA syndicate among others. A sizeable check from investors attests to faith in Diag-Nose.io’s innovative model of using artificial intelligence to make accurate diagnoses of chronic respiratory disorders.

About Diag-Nose.io

Founded in 2020, Melbourne, Australia headquartered Diag-Nose.io, is a company specializing in transcribing the united airway in the most holistic precision diagnostics and drug discovery solution. With biological interplay on the lung/nasal axis at its center of focus, the company Diag-Nose aims to revolutionize respiratory care for all time under the unifying concept of “unified airway.” 

Diag-Nose was founded by co-founders. A group of medical and scientific experts are attached to this innovative venture:

Eldin Rostom: He is the CEO, for which he has been identified as a visionary leader. He also won a place on the Forbes 30 Under 30 Asia list for Healthcare & Science in 2024.

Dr. Brian Wang: He is a Co-founder and Co-Scientific Officer. Graduating from Stanford University’s highly regarded EENT Innovation Biodesign program, he has profound knowledge in otolaryngology and in biomedical innovation.

Dr. Josie Xu: Co-founder, contributing her medical expertise to the development of the company’s diagnostic solutions.

Dr. David Yen: Co-founder and Chief Medical Officer, Dr. Yen plays a pivotal role in guiding the clinical applications of Diag-Nose.io’s technologies.

The RhinoMAP™ Platform

At the heart of Diag-Nose.io’s innovation is RhinoMAP™, an AI-driven analytics program for providing patient-specific treatment options for those with chronic respiratory diseases such as asthma, COPD, and chronic sinusitis. The device uses a proprietary nasal liquid biopsy that takes samples from patients. 

Advanced proteomics and computational biology are then used in the lab to generate an immediately translatable model of respiratory biology. RhinoMAP provides healthcare professionals with treatment effectiveness data within 48 hours, giving them the ability to make more confident and patient-specific care decisions. 

Funding Details

The seed round funding of $3.15 million was headed by Breakthrough Victoria, along with significant contributions from Radar Ventures, a syndicate of physicians from Specialty Physician Associates (SPA), and biotech angel investors Carl Stubbings, Stephen Ho, and Richard Lipscombe. Notably, Carl Stubbings has also been announced to join Diag-Nose.io’s board as Chairperson.

Breakthrough Victoria’s investment is a testament to the belief that Diag-Nose.io will revolutionize respiratory care. The firm’s support will help in the development of the RhinoMAP™ platform and contribute to job creation in the biotechnology sector.

Radar Ventures’ participation underlines the growing interest in AI-driven healthcare solutions, especially those addressing chronic respiratory diseases affecting millions worldwide.

Read more

1. AdvanCell Raises $112M to Advance Radiopharmaceutical Cancer Therapies
2. Retro Biosciences Aims to Extend Human Lifespan with $1 Billion Funding Initiative
3. Portal Biotechnologies Secures $7M to Revolutionize Cell Engineering

Clinical Trials and Future Plans

Diag-Nose.io is now conducting clinical trials with 200 Victorians to validate the effectiveness of the RhinoMAP™ platform. The company is planning to make the tool widely available next year, possibly changing the landscape of treatment for respiratory diseases. 

The recent funding will support the expansion of Diag-Nose.io’s operations, including the establishment of new offices in Houston, Texas, and Bethlehem, Pennsylvania. These strategic expansions are designed to foster partnerships with local health systems and advance clinical research efforts in the United States.

Addressing a Global Health Challenge

The diseases mean respiratory diseases that are practically affecting more than 450 million people worldwide through significant healthcare costs and thus patient quality of life. Traditional diagnosing methods largely depend on subjective patient-reported outcomes, and this in most cases leads to inefficacies and high failure rates. 

This is precisely why Diag-Nose.io’s RhinoMAP platform provides objective, data-driven insights that result in the forming of personalized treatment plans and the expectation of eliminating symptoms and enhancing patient outcome.